Silence Therapeutics provides SLN360, SLN124 clinical program updates

Silence Therapeutics provided the following SLN360 and SLN124 program updates during a presentation at the 41st Annual J.P. Morgan Healthcare Conference: The first subjects have been dosed in the SLN360 phase 2 study in high-risk atherosclerotic cardiovascular disease. The company plans to complete enrollment in the study in the fourth quarter of 2023. Silence expects data from the ongoing phase 1 multiple dose study in subjects with high lipoprotein(a) and stable ASCVD in the fourth quarter of 2023. In the single dose study evaluating healthy volunteers with high Lp(a), participants who received SLN360 saw median maximal Lp(a) reductions of 96% and 98%, respectively. Sites are open for enrollment in the SLN124 phase 1/2 study in polycythemia vera. The SLN124 PV study is a two-part study which includes a phase 1 open-label, dose finding study followed by a phase 2 randomized, double-blind, placebo-controlled parallel arm study. Silence expects data from the ongoing phase 1 multiple dose study of SLN124 in thalassemia patients in the fourth quarter of 2023. "2023 is poised to be an important and exciting year for Silence," said Craig Tooman, President and CEO of Silence. "We were pleased to initiate dosing in the SLN360 phase 2 ASCVD study and are very encouraged by the enthusiasm for this program. We also kicked off the SLN124 PV study and look forward to providing further updates as we advance the program this year. We remain very pleased with the prospects for our mRNAi GOLD platform."